Is BPC-157 Legal in 2026? The Complete Status Update
Removed from Category 2 after the nominations were withdrawn, then recommended by the PCAC at 8-6. Here is what that advisory vote means, what it does not mean, and what remains unresolved as of October 2026.
The Short Answer
BPC-157 is not prohibited, not formally authorized, and not FDA approved. It sits in a regulatory middle ground that has more legal nuance than most coverage acknowledges.
Here is what has actually happened, in order: FDA removed BPC-157 from Category 2 in 2026 after the relevant nominations were withdrawn, while electing to continue evaluating BPC-157 free base and acetate. The advisory committee then voted 8-6 in July 2026 to recommend both forms for the 503A Bulks List, contrary to FDA staff’s recommendation. That vote is advisory and did not itself put BPC-157 on the list.
The 503A Bulks List is the formal federal pathway for use of a non-monograph, non-approved bulk drug substance in 503A compounding. The advisory vote is one step in that process; final agency action requires separate notice-and-comment rulemaking.
Because compounding law also depends on the specific statutory pathway, pharmacy, prescriber, state law, and FDA enforcement policy, this page should not be read as a legal opinion about any particular transaction.
The Five Things People Confuse
The BPC-157 conversation is dogged by conflations. Five distinct regulatory concepts get treated as interchangeable, and the confusion leads people to overestimate or underestimate what has changed. Here is each one, separately.
1. Category 2 Removal ≠ Legal to Compound
When BPC-157 was placed on the FDA’s Category 2 list, that was an explicit prohibition: substances on Category 2 “may not be compounded.” Removal on April 23, 2026 lifted that prohibition. But lifting a ban is not the same as granting authorization. It removed a barrier without creating an affirmative pathway. Think of it as unlocking a door but not opening it.
2. PCAC Recommendation ≠ FDA Decision
The Pharmacy Compounding Advisory Committee is exactly what its name says: advisory. The 8-6 vote on July 23 was a recommendation to the FDA, not a decision by the FDA. The agency is not required to follow it. Historically, departing from a favorable PCAC recommendation without explanation would be procedurally unusual, but it has happened. The full PCAC results breakdown covers all seven peptides that were reviewed.
3. Removal from Category 2 ≠ Placement on the 503A Bulks List
Removal from Category 2 did not itself place BPC-157 on the 503A Bulks List. FDA’s interim policies and the formal Bulks List are distinct regulatory concepts, and the July advisory vote did not complete the rulemaking process.
4. Compounding Access ≠ FDA Approval
Even if BPC-157 is formally placed on the 503A Bulks List, it will not be an “FDA-approved drug.” FDA approval requires Phase I/II/III clinical trials, a new drug application, and an agency determination of safety and efficacy. None of that has happened with BPC-157. It has over 300 published preclinical studies but limited controlled human data. The compounding pathway exists precisely for substances that have not gone through the approval pipeline.
5. FDA Status ≠ WADA Status
BPC-157 is prohibited by the World Anti-Doping Agency under the S0 category of non-approved substances. A prescription from a licensed physician does not create a WADA exemption. Athletes subject to anti-doping testing risk sanctions regardless of how they obtained BPC-157. The FDA and WADA operate on entirely separate regulatory frameworks.
The Regulatory Timeline
Research Products vs. Pharmacy Compounding
Research-use-only products and pharmacy-compounded drug products are not the same regulatory category. A research vendor label does not make a product suitable for human use, while a compounded drug must fit the applicable federal and state compounding framework.
For 503A compounders, FDA explains that a bulk substance generally must meet an applicable USP/NF monograph, be a component of an FDA-approved drug, or appear on the 503A Bulks List, subject to the agency's applicable interim policies. BPC-157's July 2026 PCAC recommendation did not itself change those statutory requirements.
Prescription-based pharmacy compounding is governed by federal and state law and depends on the substance's regulatory status. The July PCAC vote was advisory, not a blanket authorization.
RUO products are sold for research purposes and are not FDA-approved drugs. A COA may describe a tested batch, but it does not establish clinical safety, sterility, dosing accuracy, or suitability for human administration.
What BPC-157 Is Studied For
BPC-157 — Body Protection Compound-157 — is a synthetic pentadecapeptide derived from a protein found in human gastric juice. It is one of the most widely researched peptides in the compounding space, with over 300 published preclinical papers documenting its profile across multiple systems.
The research literature covers tissue repair and wound healing, gastrointestinal protection and healing (including studies relevant to ulcerative colitis, the indication the FDA reviewed at the PCAC meeting), tendon and ligament recovery, musculoskeletal repair, and neuroprotective effects. The preclinical evidence is extensive, but it is important to note that most of this research has been conducted in animal models. Controlled human clinical trial data remains limited.
BPC-157 is commonly discussed in the context of recovery stacking, where it is paired with TB-500 for what the biohacker community calls the “Wolverine stack.” Both peptides received favorable PCAC recommendations. For a detailed look at the research and evidence limitations, see our full BPC-157 profile page.
PeptideOnline presents dosing information in the context of “what providers typically prescribe” and published research protocols. We do not provide direct medical advice or recommend specific protocols. Dosing should be determined by a licensed healthcare provider based on your individual clinical situation and bloodwork. See our prescribing guide for finding a qualified provider.
The Oral BPC-157 Question
One of the most common questions in the peptide space is whether oral BPC-157 works. The interest is driven by a straightforward reality: many people who want BPC-157’s benefits are unwilling to inject. Search volume data shows oral peptide queries running at roughly 2.3 times the volume of injectable-only peptide queries.
The preclinical research on oral BPC-157 is most developed in gastrointestinal contexts, which makes biochemical sense — the peptide is derived from gastric juice and may have particular relevance to the gut lining when delivered directly to the GI tract. For systemic applications like tendon repair or musculoskeletal recovery, injectable administration provides more direct bioavailability.
Both forms are available through research vendors and through some compounding pharmacies. The choice between oral and injectable is a clinical decision best made with a provider who understands the intended application. We cover this in detail in our upcoming article on oral BPC-157 bioavailability.
What to Watch For Next
The next milestone is the FDA’s Notice of Proposed Rulemaking. When that publishes, it will be the first concrete signal of whether the agency intends to follow the PCAC’s recommendation. Given that HHS Secretary Kennedy has been publicly supportive of expanding peptide access, and that the NCPA has reported he will need to formally approve additions to the list, the political environment appears favorable.
However, the FDA’s career scientists recommended against listing BPC-157, and the rulemaking process gives the agency another opportunity to raise safety concerns, request additional data, or narrow the scope of approved uses. The public comment period that follows the NPRM will be the last formal opportunity for stakeholders to weigh in.
A second PCAC meeting is also scheduled before February 2027 to review five additional peptides. The specific substances and dates have not yet been announced.
Separately, the 503B exclusion of GLP-1 drugs (semaglutide, tirzepatide, liraglutide) is expected to be finalized soon, which will reshape the telehealth peptide market and may accelerate commercial interest in non-GLP-1 peptides like BPC-157.
Frequently Asked Questions
Sources
This article draws on the FDA’s official PCAC meeting page and briefing document (docket FDA-2025-N-6895), the HHS April 23, 2026 Category 2 removal announcement, vote tallies reported by AJMC and NCPA, regulatory analysis from McDermott Will & Emery, Holt Law, and Nextera Legal, and clinical access frameworks described by Affinity Whole Health and RethinkPeptides. WADA prohibited list (2026 edition), S0 category. All regulatory claims have been cross-referenced across multiple legal and pharmaceutical sources.